


RSC Biomolecular Sciences

Edited by Antony D Buss and Mark S Butler

Natural Product Chemistry for Drug Discovery



RSC Publishing

Natural Product Chemistry for Drug Discovery

Edited by

Antony D. Buss and Mark S. Butler

MerLion Pharmaceuticals, Singapore

RSC Publishing

RSC Biomolecular Sciences No. 18

ISBN: 978-0-85404-193-0

ISSN: 1757-7136

A catalogue record for this book is available from the British Library

© Royal Society of Chemistry 2010

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our website at www.rsc.org

Natural Product Chemistry for Drug Discovery

Abstract: This review discusses the importance of natural product chemistry in drug discovery. It highlights the role of natural products as a source of novel chemical structures and their potential as lead compounds for the development of new drugs. The review also discusses the challenges associated with the isolation and characterization of natural products and the need for interdisciplinary approaches to overcome these challenges.

1. Introduction
2. Importance of Natural Products in Drug Discovery
3. Sources of Natural Products
4. Isolation and Characterization of Natural Products
5. Natural Products as Lead Compounds
6. Challenges in Natural Product Chemistry
7. Interdisciplinary Approaches
8. Conclusion
9. Acknowledgments
10. References
11. Appendix
12. Glossary
13. Index
14. Author Biographies
15. Table of Contents
16. List of Figures
17. List of Tables
18. List of Abbreviations
19. List of Symbols
20. List of Equations
21. List of Chemical Structures
22. List of Biological Assays
23. List of Clinical Trials
24. List of Patents
25. List of Publications
26. List of Conferences
27. List of Workshops
28. List of Seminars
29. List of Courses
30. List of Books
31. List of Journals
32. List of Websites
33. List of Databases
34. List of Software
35. List of Equipment
36. List of Reagents
37. List of Solvents
38. List of Buffers
39. List of Media
40. List of Cells
41. List of Animals
42. List of Plants
43. List of Fungi
44. List of Bacteria
45. List of Viruses
46. List of Parasites
47. List of Insects
48. List of Mammals
49. List of Birds
50. List of Fish
51. List of Reptiles
52. List of Amphibians
53. List of Mollusks
54. List of Arachnids
55. List of Invertebrates
56. List of Microbes
57. List of Organisms
58. List of Species
59. List of Genus
60. List of Family
61. List of Order
62. List of Class
63. List of Phylum
64. List of Kingdom
65. List of Domain
66. List of Life
67. List of Matter
68. List of Energy
69. List of Information
70. List of Time
71. List of Space
72. List of Mass
73. List of Charge
74. List of Temperature
75. List of Pressure
76. List of Humidity
77. List of Wind
78. List of Rain
79. List of Snow
80. List of Ice
81. List of Fire
82. List of Earth
83. List of Air
84. List of Water
85. List of Plants
86. List of Animals
87. List of Humans
88. List of Societies
89. List of Cultures
90. List of Religions
91. List of Philosophies
92. List of Sciences
93. List of Arts
94. List of Sports
95. List of Games
96. List of Hobbies
97. List of Professions
98. List of Occupations
99. List of Careers
100. List of Industries

This review is intended to provide a comprehensive overview of the field of natural product chemistry for drug discovery. It is not intended to be a comprehensive review of the field, but rather a starting point for further research.

The authors would like to thank the following individuals for their contributions to this review: [Names of authors].

RSC Biomolecular Sciences

Editorial Board:

Professor Stephen Neidle (Chairman), *The School of Pharmacy, University of London, UK*

Dr Marius Clore, *National Institutes of Health, USA*

Professor Roderick E Hubbard, *University of York and Vernalis, Cambridge, UK*

Professor David M J Lilley FRS, *University of Dundee, UK*

Titles in the Series:

- 1: Biophysical and Structural Aspects of Bioenergetics
- 2: Exploiting Chemical Diversity for Drug Discovery
- 3: Structure-based Drug Discovery: An Overview
- 4: Structural Biology of Membrane Proteins
- 5: Protein–Carbohydrate Interactions in Infectious Disease
- 6: Sequence-specific DNA Binding Agents
- 7: Quadruplex Nucleic Acids
- 8: Computational and Structural Approaches to Drug Discovery: Ligand–Protein Interactions
- 9: Metabolomics, Metabonomics and Metabolite Profiling
- 10: Ribozymes and RNA Catalysis
- 11: Protein–Nucleic Acid Interactions: Structural Biology
- 12: Therapeutic Oligonucleotides
- 13: Protein Folding, Misfolding and Aggregation: Classical Themes and Novel Approaches
- 14: Nucleic Acid–Metal Ion Interactions
- 15: Oxidative Folding of Peptides and Proteins
- 16: RNA Polymerases as Molecular Motors
- 17: Quantum Tunnelling in Enzyme-Catalysed Reactions
- 18: Natural Product Chemistry for Drug Discovery

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Sales and Customer Care, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 432360, Fax: +44 (0)1223 420247, Email: sales@rsc.org

Visit our website at <http://www.rsc.org/Shop/Books/>

Preface

Natural products hold a special place in drug discovery having provided and inspired numerous life saving medicines and medical breakthroughs, particularly in the treatment of infectious diseases, cancer, hypercholesterolemia and immunological disorders. Twenty one drugs approved for marketing between 2003 and 2008 owe their existence to natural product leads discovered from mainly actinomycete, bacteria and fungal sources.¹ It has been our intention with this book to not only provide insights into the likely sources and methodologies that may be used to discover new natural product based drugs in the future, but also to stress the utility and importance of this approach to drug discovery in terms of new clinical candidates and recent commercial successes.

The final section of this book provides fascinating accounts of the twists, turns and pitfalls, as well as the role serendipity played, in the successful development and commercialisation of daptomycin and micafungin. Accounts of natural product derived drug candidates which are currently being evaluated in clinical trials may be found in Chapters 11–13, with salinosporamide A and bevirimat described in detail. The pipeline of 36 drug candidates which are in late stage clinical development may imply a continuing role for natural products in drug discovery, but we will return to this issue towards the end of this preface. Before then, let us look at the earlier chapters which follow in this book.

Well known for their thorough analyses of the sources of new and approved drugs, Newman and Cragg set the scene in Chapter 1 with a discussion on the historical influence natural products have had on the drug discovery process, with particular emphasis on antibacterial, antifungal and anticancer agents. The reason for the success of natural product chemistry in drug discovery is multifactorial, but certainly includes the unique “chemical space” that is occupied by such molecules. A particularly elegant account of how this applies to the required physicochemical property space for antibacterial compounds

has been made recently by O'Shea and Moser.² In Chapter 2, Singh and Culberson expand on this theme with a comparison of the diversity of natural products with various synthetic compound libraries and their impact as drug leads in general.

La Clair, in Chapter 3, adopts a cinematic approach whilst delving into the mechanistic modes of action and the complex roles that natural products play. Included in this account are descriptions of how natural products have led to a better understanding of the regulation of tubulin and actin assembly in tumour cells and to the identification of an array of new, putative anticancer drug targets.

In Chapter 4, Cordell thoroughly evaluates the impact of the Convention on Biological Diversity (CBD) and other related agreements on academic and industrial natural product research. While the CBD has resulted in the development of laws and practices that have protected the sovereign rights of countries over their genetic resources, it has also led to natural product research programmes being compromised in scope and has perhaps contributed, at least in part, to many pharmaceutical companies terminating their natural product research activities.

Plants, microorganisms and, to a lesser extent, macromarines have been the main sources of natural product based drugs (produced as secondary metabolites). Reviews of these traditional sources of naturally occurring chemical compounds are found in Chapters 5–7, together with hints and suggestions as to how these sources may be better utilised to continue supplying new drug leads in the future.

Advances in high throughput screening technology, particularly with regard to detection methods and readouts, are reviewed in Chapter 8. These advances in biological screening, coupled with improvements in chromatographic and analytical techniques (highlighted in Chapter 9), have led to a significant reduction in the time required to purify active compounds from complex mixtures and to determine their chemical structures. In addition to conventional natural product discovery approaches, new versions of two major classes of natural products, the non-ribosomal peptides and polyketides, can now be engineered and produced using genetic manipulation techniques because of the ability to correlate gene sequence with amino acid sequence and thus, the chemical structure of the biosynthetic product. In Chapter 10, Udworthy reviews the advances made in this field of combinatorial biosynthesis over the last 15 years, together with an account of some of the significant technical limitations that still need to be overcome before the rational engineering of biosynthetic pathways can be more readily harnessed for drug discovery.

We promised to return to the earlier statement that a healthy development pipeline of natural product derived candidates implies that natural products will still have a role to play in modern day drug discovery. In fact, this is far from reality. Firstly, these late-stage clinical candidates reflect the output from research activities undertaken at least 10 years ago and certainly not the current situation. Secondly, there is a lack of truly novel chemical templates in the pipeline and thirdly, it is clear that very few pharmaceutical companies remain engaged, at least internally, in natural product drug discovery activities.

In 2007, the US Food and Drug Administration approved only 16 new molecular entities, the lowest in a single year since 1983.³ Despite a slight improvement in 2008, there remains a disturbing overall decline in pharmaceutical R&D productivity that is exacerbated by exponential rises in R&D costs, erosion of sales as many key products face patent expiration and increasing regulatory hurdles. With a burgeoning and aging population, the need for innovative new medicines throughout the world will not diminish. So is there a place for natural product based drug discovery in the future and, if so, where will new biologically active natural products come from?

In this book many of the significant technical advances which have accelerated the screening, purification and structural identification of bioactive natural products have been highlighted. As Bugni *et al.* remind us in Chapter 9, many of the previous bottlenecks that made natural products discovery a slow, laborious process have indeed been removed. However, for natural product based drug discovery to become cost effective and remain competitive, a number of key problems must be addressed, including the continual discovery of known compounds from existing natural product extract collections, the scarcity of novel bioactive chemical templates and the challenge of structurally modifying sometimes complex, often oxygen-rich, chiral natural product lead structures.

With the concept that secondary metabolites have evolved to specifically interact with protein targets and that these are not so different from human proteins, the construction of synthetic compound libraries inspired or based on natural product templates will continue to gain popularity and general acceptance as a valid drug discovery approach. Given that access to biologically relevant, drug-like chemical space is central to the drug discovery process and that natural products often occupy very different areas of this “space” compared to synthetic compounds,⁴ then we believe that the search for drug leads from natural products offers a complimentary and much needed approach to other drug discovery strategies.

Antony D. Buss and Mark S. Butler
MerLion Pharmaceuticals, Singapore

References

1. M. S. Butler, *Nat. Prod. Rep.*, 2008, **25**, 475.
2. R. O'Shea and H. E. Moser, *J. Med. Chem.*, 2008, **51**, 2871.
3. B. Hughes, *Nat. Rev. Drug Discov.*, 2009, **8**, 93.
4. J. Rosen, J. Gottfries, S. Muresan, A. Backlund and T. I. Oprea, *J. Med. Chem.*, 2009, **52**, 1953.

Contents

Section 1 Introduction to Natural Products for Drug Discovery

Chapter 1 Natural Products as Drugs and Leads to Drugs: The Historical Perspective

David J. Newman and Gordon M. Cragg

1	Ancient History (>2900 BCE to 1800 CE)	3
2	The Initial Influence of Chemistry upon Drug Discovery	6
2.1	Alkaloids	6
2.2	Aspirin	8
2.3	Digitalis	9
3	20th and 21st Century Drugs/Leads from Nature	10
3.1	Antibacterial and Antifungal Antibiotics	10
3.2	Antiviral Agents	19
3.3	Natural Product Based Antitumour Agents	21
4	Final Comments	23
	References	24

Chapter 2 Chemical Space and the Difference Between Natural Products and Synthetics

Sheo B. Singh and J. Chris Culberson

1	Introduction	28
2	Sources of Organic Compounds and Drug Leads	29
2.1	Natural Products	29
2.2	Natural Product Derivatives	29
3	Synthetic Compounds	30
3.1	Synthetic Compound Libraries	30
3.2	Combinatorial Libraries	30

RSC Biomolecular Sciences No. 18

Natural Product Chemistry for Drug Discovery

Edited by Antony D. Buss and Mark S. Butler

© Royal Society of Chemistry 2010

Published by the Royal Society of Chemistry, www.rsc.org

3.3	Diversity-Oriented Synthetic (DOS) Libraries	31
3.4	Fragment Libraries	31
4	Lipinski's "Rule of Five" for Orally Active Drugs	32
5	Assessment of Diversity of Libraries with Respect to Drugs	33
5.1	Molecular Weight	34
5.2	Distribution of Atom Types: H-bond Donors and Acceptors	35
5.3	Lipophilicities (Log P)	37
5.4	Chiral Centres	37
5.5	Rotatable Bonds, Unsaturation, Rings, Chains and Ring Topology	38
6	Principal Component Analysis (PCA)	39
7	Conclusions	40
	References	42

Chapter 3 Mechanism of Action Studies

James J. La Clair

1	Introduction	44
2	Some Like It Hot: Esperamicin A ₁ , Neocarzinostatin and Related Eneidyne Antibiotics	45
3	To Catch a Mockingbird: Taxol, Epothilone and the Microtubule	47
4	Notorious: Jasplakinolide, Alias Jaspamide and Actin	51
5	Invasion of the Pathway Snatchers: Artemisinin	53
6	Once Upon a Time in the Immune System: FK-506, Cyclosporin A and Rapamycin	55
7	Back to the Cytoskeleton: the Phorbadoxoles	56
8	It's a Wonderful Target: VTPase and its Targeting by Apicularen A, Salicylhalamide A and Palmerolide A	59
9	Double Indemnity: Bistramide A	61
10	The Matrix: the Pladienolides and Splicing Factor SF3b	62
11	The Unusual Suspects: (+)-Avrainvillamide	65
12	Close Encounters of a Third Kind: Ammosamides, Blebbistatin and Myosin	67
13	The End	69
	References	69

Section 2 Sources of Compounds

Chapter 4 The Convention on Biological Diversity and its Impact on Natural Product Research*Geoffrey A. Cordell*

1	Introduction	81
2	Historical Perspective	85
3	The Convention on Biological Diversity	87
4	Implementation and Regulatory Outcomes of the CBD	92
5	Assessment of Impact	95
5.1	An Overview and Some Examples	95
5.2	An Informal Survey	100
5.3	Survey Results	101
5.4	Survey Overview	116
6	The TRIPS Agreement and the CBD	116
7	Other Aspects and Outcomes	123
7.1	The International Cooperative Biodiversity Group Programme	125
8	Some Recommendations	127
9	A Web of Interconnectedness	130
10	A Different World	131
11	Conclusions	133
	Acknowledgements	134
	References	135

Chapter 5 Plants: Revamping the Oldest Source of Medicines with Modern Science*Giovanni Appendino and Federica Pollastro*

1	Introduction	140
2	Plant Secondary Metabolites vs. Secondary Metabolites of Other Origin	143
3	Unnatural Sources of Plant Secondary Metabolites	146
4	Critical Issues in Plant-based Natural Product Drug Discovery	149
4.1	Intellectual Property (IP) Issues	149
4.2	Pleiotropy and Synergy	151
4.3	Extract Libraries vs. Fraction (Peak) Libraries vs. Compound Libraries	153
4.4	Removal of Interfering Compounds	155
5	Selection Strategies for Plant-Based Natural Product Drug Discovery	156
5.1	Ethnopharmacology	156

5.2	Zoopharmacy and Animal Toxicology	157
5.3	Traditional Medicine	158
5.4	Dietary Plants and Spices	159
6	The Pharmaceutical Relevance of Plants	161
6.1	Plants as a Source of Lead Structures and Drugs	161
6.2	Plants as a Source of Standardised Extracts	163
7	Conclusions	167
	References	168

Chapter 6 Macromarines: A Selective Account of the Potential of Marine Sponges, Molluscs, Soft Corals and Tunicates as a Source of Therapeutically Important Molecular Structures

Jennifer Carroll and Phillip Crews

1	Introduction	174
1.1	Macroorganisms: Outstanding Success in Producing Viable Drug Leads	175
1.2	Setting that Ara A and Ara C Story Straight	175
1.3	The Potential Role of Invertebrate Associated Microorganisms and Secondary Metabolite Production	176
1.4	Macromarine Evolution	176
2	Sponges	177
2.1	Natural History of Sponges—a Primitive Phylum with Remarkable Biosynthetic Capabilities	177
3	Molluscs	186
3.1	Natural History of Molluscs—the Source of Numerous Preclinical Drug Leads	186
4	Soft Corals	189
4.1	Natural History of Cnidarians—the “Stinging Nettle” of the Sea	189
5	Tunicates	192
5.1	Natural History of Tunicates—Our Closest Marine Invertebrate Relations	192
6	Conclusions	194
	References	195

Chapter 7 Microorganisms: Their Role in the Discovery and Development of Medicines

Cedric Pearce, Peter Eckard, Iris Gruen-Wollny and Friedrich G. Hansske

1	Introduction	215
2	Bacteria	218
3	Fungi	220
4	Terrestrial and Marine Microorganisms	221

5	Microbial Culture Collections	222
6	Evidence for “Uncultivable” Microbes	223
7	Metagenomic Approach to Access Uncultivable Microbes	224
8	Culturing Techniques to Produce Secondary Metabolites	225
9	Evidence for New Biosynthetic Pathways in Known Microbes	227
10	Genetic Pathway Engineering and Modulation of Post-translational Modification to Generate Novel Compounds	227
11	Microbial Secondary Metabolites with Unique Biological Activity and Chemical Diversity	228
12	Microbial Secondary Metabolites with Unique Pharmacological Activity	231
13	Conclusions	232
	Structures Discussed in Tables 7.2 and 7.3	233
	References	236

Section 3 Advances in Technology

Chapter 8 **Advances in Biological Screening for Lead Discovery** *Christian N. Parker, Johannes Ottl, Daniela Gabriel and Ji-Hu Zhang*

1	Introduction	245
1.1	Natural Product Screening and the Development of HTS	247
1.2	Chapter Objectives	247
2	Types of HTS Assays	247
2.1	<i>In vitro</i> Biochemical Assays	248
2.2	Cell-based Assays	255
2.3	Modelling to Identify False Positives and Negatives	261
3	Emerging Trends	262
3.1	New HTS Approaches	262
	Acknowledgements	265
	References	265

Chapter 9 **Advances in Instrumentation, Automation, Dereplication and Prefractionation** *Tim S. Bugni, Mary Kay Harper, Malcolm W.B. McCulloch and Emily L. Whitson*

1	Introduction	272
2	Dereplication	274

3	Extraction	275
4	Prefractionation	276
5	Isolation and Purification	278
5.1	Automated Purification	279
6	HPLC Separation Technologies	279
7	Mass Spectrometry	282
8	NMR	285
8.1	Probe Technology	285
8.2	Structure Elucidation	287
8.3	Methods for Fast NMR	288
8.4	Automated Structure Elucidation	290
8.5	Configuration by NMR	291
8.6	Residual Dipolar Couplings	292
9	Conclusions	292
	References	293

Chapter 10 Natural Product Combinatorial Biosynthesis: Promises and Realities

Daniel W. Udway

1	Introduction	299
2	A Brief History of Natural Product Biosynthesis	300
3	Promises	304
4	Realities	307
5	Future Biotechnological Promises	312
	References	314

Section 4 Natural Products in Clinical Development

Chapter 11 A Snapshot of Natural Product-Derived Compounds in Late Stage Clinical Development at the End of 2008

Mark S. Butler

1	Introduction	321
2	NP-derived Drugs Launched in the Last Five Years	324
3	Late Stage NDAs and Clinical Candidates	327
3.1	Antibacterial	327
3.2	Oncology	332
3.3	Other Therapeutic Areas	340
4	Conclusions and Outlook	342
	References	343

Chapter 12 From Natural Product to Clinical Trials: NPI-0052 (Salinisporamide A), a Marine Actinomycete-Derived Anticancer Agent

Kin S. Lam, G. Kenneth Lloyd, Saskia T. C. Neuteboom, Michael A. Palladino, Kobi M. Sethna, Matthew A. Spear and Barbara C. Potts

1	Introduction	355
1.1	Bioprospecting Marine Actinomycetes and the Discovery of <i>Salinispora</i> and NPI-0052	355
1.2	The Ubiquitin-Proteasome System as a Target for Drug Development	356
2	Mechanism of Action	358
3	Microbiology of <i>Salinispora tropica</i> , Fermentation and Scale-up	359
4	Structural Biology and Structure-Activity Relationship Studies	361
5	Translational Biology	363
6	IND-Enabling Studies of NPI-0052	364
7	API Manufacturing	365
8	Formulation Development and Drug Product Manufacturing	366
9	Pharmacodynamics	367
10	Pharmacokinetics	368
11	Clinical Trials	368
12	Concluding Remarks	370
	Acknowledgements	370
	References	370

Chapter 13 From Natural Product to Clinical Trials: Bevirimat, a Plant-Derived Anti-AIDS Drug

Keduo Qian, Theodore J. Nitz, Donglei Yu, Graham P. Allaway, Susan L. Morris-Natschke and Kuo-Hsiung Lee

1	Introduction	374
2	Bioactivity-directed Fractionation and Isolation	375
3	Lead Identification	375
4	Lead Optimisation and SAR Study	377
4.1	Modification of the BA Triterpene Skeleton	377
4.2	Modification on C-3 Position of BA	378
4.3	Introduction of C-28 Side Chain into BA	382
4.4	Bifunctional BA Analogues—Potential for Maturation Inhibitor Development	383
5	Mechanism of Action Studies of Bevirimat	384

6	Preclinical Studies of Bevirimat	385
7	Clinical Trials and Current Status of Bevirimat	387
8	Conclusions	388
	Acknowledgements	388
	References	388

Section 5 Case Studies of Marketed Natural Product-derived Drugs

Chapter 14 Daptomycin

Richard H. Baltz

1	Introduction	395
2	Discovery of A21987C and Daptomycin	396
2.1	Enzymatic Cleavage of the Fatty Acid Side Chain	396
2.2	Chemical Modifications of the A21978C Core Peptide	397
3	Biosynthesis	397
3.1	Analysis of the Daptomycin Biosynthetic Gene Cluster	397
3.2	Daptomycin Structure	398
4	Mechanism of Action Studies	399
4.1	Daptomycin Resistant Mutants	400
5	Antibacterial Activities	401
5.1	<i>In vitro</i> Activities	401
5.2	<i>In vivo</i> Activities in Animal Models	402
6	Clinical Studies	402
6.1	Eli Lilly and Company	402
6.2	The Passing of the Baton	403
6.3	Cubist Pharmaceuticals	403
7	Lessons Learned	404
8	Epilogue	405
	References	405

Chapter 15 Micafungin

Akihiko Fujie, Shuichi Tawara and Seiji Hashimoto

1	Introduction	410
1.1	New Antifungal Compounds Discovered at Fujisawa (a Predecessor of Astellas Pharma Inc.)	411
1.2	1,3- β -Glucan Synthase Inhibition and Echinocandins	413
2	From the Discovery of FR901379 to Clinical Studies of FK463 (Micafungin)	414
2.1	Discovery of FR901379	414
2.2	Generation of Lead Compound FR131535	418

2.3	Lead Optimisation Leading to the Discovery of FK463 ^{12,13}	421
2.4	Preclinical Studies of FK463	425
2.5	Industrial Manufacturing of Micafungin	426
2.6	Clinical Studies of FK463	426
3	Conclusions	427
	Acknowledgements	427
	References	427

Subject Index	429
----------------------	-----